<DOC>
	<DOCNO>NCT00830024</DOCNO>
	<brief_summary>This study compare relative bioavailability ( rate extent absorption ) 3 mg Alprazolam Extended Release Tablets manufacture distribute TEVA Pharmaceuticals USA 3 mg XANAX XR® Tablets Pharmacia &amp; Upjohn Company follow single oral dose ( 1 x 3 mg extend release tablet ) healthy adult subject administer non-fasting condition .</brief_summary>
	<brief_title>Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Non-fasting Conditions</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method</detailed_description>
	<mesh_term>Alprazolam</mesh_term>
	<criteria>Screening Demographics : All subject select study healthy nonsmoking men woman 18 year age old time dose . The subject 's body mass index ( BMI ) less equal 30 . Screening procedure : Each subject complete screening process within 28 day prior Period I dose . Consent document screen evaluation HIV antibody determination review , discuss , sign potential participant full implementation screening procedure . Screening include general observation , physical examination , demographic , medical medication history , electrocardiogram , sit blood pressure heart rate , respiratory rate temperature . The physical examination include , may limited evaluation cardiovascular , gastrointestinal , respiratory , central nervous system . The screen clinical laboratory procedure include : Hematology : hematocrit , hemoglobin , WBC count differential , RBC count , platelet count ; Clinical Chemistry : serum creatinine , BUN , glucose , AST ( GOT ) , ALT ( GPT ) , albumin , total bilirubin , total protein , alkaline phosphatase ; HIV antibody , hepatitis B surface antigen , hepatitis C antibody screen ; Urinalysis : dipstick ; full microscopic examination dipstick positive ; Urine Drug Screen : ethyl alcohol , amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine metabolite , opiate , phencyclidine . Serum Pregnancy Screen ( female subject ) FSH ( verify postmenopausal status ; female subject ) If female : postmenopausal least 1 year serum FSH level ≥ 20mIU/mL ; surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , hysterectomy ) . Subjects recent history dug alcohol addiction abuse . Subjects presence clinically significant disorder involve cardiovascular , respiratory , renal , gastrointestinal , immunologic , hematologic , endocrine , neurologic system ( ) psychiatric disease ( determined clinical investigator ) . Subjects whose clinical laboratory test value outside accept reference range confirm reexamination deem clinically significant . Subjects demonstrate reactive screen hepatitis B surface antigen , hepatitis C antibody HIV antibody . Subjects demonstrate positive drug abuse screen screen study . Female subject demonstrate positive pregnancy screen . Female subject currently breastfeed . Subjects history allergic response ( ) alprazolam relate drug . Subjects history clinically significant allergy include drug allergy . Subjects clinically significant illness 4 week prior Period I dose ( determined clinical investigator ) . Subjects currently use report use tobacco product within 90 day Period I dose administration . Subjects take drug know induce inhibit hepatic drug metabolism 28 day prior Period I dose . Subjects report donate great 150 mL blood within 30 day prior Period I dose . All subject advise donate plasma four week complete study . Subjects report receive investigational drug within 28 day prior Period I dose . Subjects report take systemic prescription medication 14 day prior Period I dose . Subjects report intolerance direct venipuncture . Subjects report consume abnormal diet 28 day prior Period I dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>